Bivalirudin
An FDA-approved synthetic 20-amino-acid direct thrombin inhibitor used as an intravenous anticoagulant during percutaneous coronary intervention (PCI) and as a non-heparin option in patients with heparin-induced thrombocytopenia.
What is Bivalirudin?
Bivalirudin is a synthetic 20-amino-acid peptide (D-Phe-Pro-Arg-Pro-[Gly]4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu) that acts as a reversible, bivalent, direct thrombin inhibitor. It is FDA-approved (December 2000) under the brand name Angiomax — originally developed by The Medicines Company (now part of Novartis) from a Biogen-era hirudin-mimetic design — for intravenous anticoagulation in patients undergoing percutaneous coronary intervention (PCI), including those with or at risk for heparin-induced thrombocytopenia and thrombosis (HIT/HITTS). Unlike heparin, which requires antithrombin III as a cofactor and cannot inactivate clot-bound thrombin, bivalirudin binds directly to two distinct sites on the thrombin molecule — the catalytic active site and exosite 1 (the fibrinogen-recognition site) — blocking both circulating and fibrin-bound thrombin. The drug's hallmark is a self-limiting anticoagulant effect: thrombin slowly cleaves the N-terminal active-site fragment of bivalirudin, allowing the enzyme to dissociate and regain function. That short, predictable pharmacology (plasma half-life approximately 25 minutes in normal renal function) is the mechanistic basis for its niche in the cath lab.
What Bivalirudin Is Investigated For
Bivalirudin has one FDA-approved setting — intravenous anticoagulation during percutaneous coronary intervention — and a meaningful set of off-label uses in non-heparin-required situations. The PCI evidence is among the deepest in interventional cardiology: the landmark REPLACE-2 trial (Lincoff 2003) established non-inferiority versus heparin + planned glycoprotein IIb/IIIa inhibition with significantly less bleeding; HORIZONS-AMI (Stone 2008) in STEMI showed lower 30-day major bleeding and lower cardiac mortality versus heparin + GP IIb/IIIa; ISAR-REACT 4 (Kastrati 2011) showed equivalent ischemic outcomes and less bleeding versus heparin + abciximab in NSTEMI. That said, the picture became more complex when bivalirudin was compared to heparin monotherapy rather than heparin plus a GP IIb/IIIa inhibitor. HEAT-PPCI (Shahzad 2014) favored heparin monotherapy on ischemic endpoints, and MATRIX (Valgimigli 2015) showed no MACE benefit overall, though mortality and bleeding outcomes did favor bivalirudin. More recently, BRIGHT-4 (Han 2022) in Chinese STEMI patients with a post-PCI high-dose infusion once again favored bivalirudin on the composite of death or major bleeding. The honest synthesis: bivalirudin clearly reduces bleeding at the cost of a small acute stent thrombosis signal, and the net benefit depends on the comparator regimen, the duration of post-PCI infusion, and the patient's bleeding risk. The HIT indication — where heparin is contraindicated and an alternative parenteral anticoagulant is required — is where bivalirudin's role is most secure alongside argatroban, particularly for patients undergoing PCI, cardiac surgery, or ECMO. Off-label ECMO and CPB data are expanding but heterogeneous, and protocols vary meaningfully between centers.
History & Discovery
Bivalirudin's lineage begins in the medicinal leech, Hirudo medicinalis. Leech saliva contains hirudin, a 65-amino-acid peptide that binds thrombin with extraordinary affinity (Ki in the femtomolar range) via a bivalent interaction: its N-terminal portion occupies thrombin's active site while the acidic C-terminal tail docks into exosite 1, the fibrinogen-recognition site. Hirudin has been known as a natural anticoagulant since the 19th century, but therapeutic use required recombinant production and a more tractable molecular design. In the late 1980s and early 1990s, several academic and industrial groups pursued hirudin-derived synthetic peptides. The critical design leap came from John Maraganore and colleagues at Biogen, whose 1990 Biochemistry paper (Maraganore et al., Biochemistry 29:7095-7101) defined a class of bivalent peptides they named 'hirulogs.' These peptides combined the active-site-binding N-terminus (derived from the D-Phe-Pro-Arg-Pro sequence) with a flexible glycine linker and a 12-residue C-terminal segment mimicking hirudin's exosite-1-binding tail. Hirulog-1 and related compounds demonstrated potent anticoagulant activity in vitro and in vivo. Hirulog-8 — the molecule later renamed bivalirudin — emerged from this program as the most clinically tractable candidate, with favorable pharmacokinetics and the self-limiting cleavage-based off-switch that distinguished it from the irreversible hirudin analogues. Biogen licensed the hirulog program, and in the mid-1990s the drug passed to The Medicines Company, a startup founded in 1996 specifically to finish clinical development and commercialize hirulog-8/bivalirudin after larger pharma firms had de-prioritized it. The Bivalirudin Angioplasty Trial (BAT), published by Bittl and colleagues in NEJM in 1995, randomized over 4,000 patients undergoing angioplasty for unstable or postinfarction angina. Bivalirudin narrowly missed the primary efficacy endpoint but significantly reduced major bleeding — a signature result that has echoed through every subsequent bivalirudin trial. A reanalysis published in 2001 strengthened the overall case for bivalirudin in the intent-to-treat population. The FDA approved Angiomax (bivalirudin) in December 2000 for anticoagulation in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty. The label subsequently expanded, following the REPLACE-2 trial (Lincoff et al., JAMA 2003), to cover PCI more broadly and to include patients with or at risk for heparin-induced thrombocytopenia. The HORIZONS-AMI trial (Stone et al., NEJM 2008) established the STEMI use case and prompted further label expansion. Commercially, Angiomax became a major asset for The Medicines Company. Patent litigation over the US composition-of-matter and use patents extended the branded exclusivity through a well-known 'patent term adjustment' controversy resolved in court in The Medicines Company's favor; generic bivalirudin finally entered the US market in 2015. The Medicines Company was acquired by Novartis in 2020 (primarily for a different asset — the PCSK9 inhibitor inclisiran), but the bivalirudin franchise lives on in multiple generic formulations globally. Scientifically, bivalirudin's landscape has evolved substantially. Through the 2000s it was the preferred anticoagulant for many US cath labs, displacing heparin + GP IIb/IIIa inhibitor regimens. The 2014 HEAT-PPCI trial and the 2015 MATRIX trial challenged that primacy by comparing bivalirudin to heparin monotherapy (with bailout-only GP IIb/IIIa), producing more equivocal results and narrowing the perceived bleeding advantage. The 2022 BRIGHT-4 trial then revived the case for bivalirudin when paired with a prolonged post-PCI high-dose infusion. Contemporary guidelines treat both strategies as acceptable, and the choice reflects operator experience, bleeding risk, and institutional protocol. Bivalirudin remains a core agent for HIT-related PCI and cardiac surgery — a setting where heparin is contraindicated and alternatives are narrow.
How It Works
Thrombin is the enzyme that drives blood clot formation by converting fibrinogen into fibrin. Bivalirudin is a peptide that physically grabs thrombin in two places at once — its active site (where it cuts fibrinogen) and a nearby recognition pocket — preventing it from working. Because it holds thrombin directly, it also blocks thrombin that has already embedded itself inside an existing clot, which heparin cannot do. The grip is reversible: thrombin slowly chews off a piece of the bivalirudin molecule and escapes after a few minutes, which is why the drug is used as a short IV infusion during procedures and clears rapidly afterward.
Bivalirudin is a rationally designed bivalent peptide inhibitor of thrombin, derived from the structural logic of hirudin — the 65-amino-acid natural anticoagulant from the medicinal leech Hirudo medicinalis. John Maraganore and colleagues at Biogen in 1990 published the design of a synthetic class they termed 'hirulogs' (Biochemistry 29:7095-7101), combining the active-site-binding N-terminus of hirudin (D-Phe-Pro-Arg-Pro, a mimetic of the hirudin 1–4 residues) with a four-glycine linker and a 12-residue C-terminal segment derived from the hirudin 53–64 exosite-1-binding tail (Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu). The result is a single 20-amino-acid peptide that spans thrombin's two key recognition regions simultaneously. Mechanistically, bivalirudin binds thrombin in a 1:1 stoichiometry with dual anchoring: the N-terminal tetrapeptide occupies the catalytic active site (the serine-protease cleft), while the anionic C-terminal dodecapeptide docks into exosite 1 (the fibrinogen-binding site). This bivalent occupation blocks thrombin's ability to cleave fibrinogen, activate factor V, activate factor VIII, activate factor XIII, and activate platelets via PAR-1 — the full downstream coagulation and platelet-activation cascade driven by thrombin is silenced. Crucially, bivalirudin's grip is reversible. Thrombin slowly cleaves the Arg-Pro bond within the active-site-binding N-terminus (a physiological substrate bond it normally cleaves in prothrombin and fibrinogen), which disables the active-site anchor. The cleaved bivalirudin then dissociates, and thrombin regains catalytic function. This cleavage kinetics produces the drug's self-limiting anticoagulant profile — an intrinsic 'off switch' that contributes to its short pharmacodynamic duration and is a core design advantage over the irreversible binding of earlier hirudin derivatives. Five mechanistic points distinguish bivalirudin from heparin: (1) no antithrombin III cofactor requirement — direct binding only; (2) inhibits both free thrombin and fibrin-bound thrombin (heparin-antithrombin complexes cannot access fibrin-bound thrombin); (3) no interaction with platelet factor 4 — bivalirudin cannot trigger HIT; (4) no binding to plasma proteins (e.g., histidine-rich glycoprotein) that buffer heparin's anticoagulant effect, producing a more predictable dose-response; (5) primarily non-renal clearance via proteolysis (approximately 80%) with about 20% renal clearance of intact drug, with half-life of approximately 25 minutes in normal renal function. These properties are the mechanistic basis for the drug's procedural niche: rapid, predictable, titratable anticoagulation for the duration of a PCI or cardiac surgery, clearing quickly enough that post-procedure bleeding risk resolves on its own.
Evidence Snapshot
Human Clinical Evidence
Very strong. Multiple large randomized trials (BAT, REPLACE-2, HORIZONS-AMI, ISAR-REACT 4, EUROMAX, HEAT-PPCI, MATRIX, BRIGHT-4) and a cumulative randomized population exceeding 50,000 patients make bivalirudin one of the most thoroughly studied anticoagulants in interventional cardiology. Evidence is strongest for procedural anticoagulation during PCI and for HIT-related indications.
Animal / Preclinical
Thorough. Thrombin biology and bivalent direct-thrombin-inhibitor pharmacology are extensively characterized across in vitro coagulation assays, thrombin crystal structures (including bivalirudin-thrombin co-crystal), and large-animal thrombosis models.
Mechanistic Rationale
Very strong. Bivalent binding at the thrombin active site and exosite 1 is structurally resolved, and the self-limiting cleavage kinetics are biochemically defined.
Research Gaps & Open Questions
What the current literature has not yet settled about Bivalirudin:
- 01Optimal post-PCI infusion duration and dose — the BRIGHT-4 2–4 hour high-dose post-PCI infusion improved outcomes vs. heparin monotherapy, but the broader generalizability of this protocol (particularly outside predominantly radial-access, East Asian STEMI populations) is still being established.
- 02Head-to-head vs. heparin monotherapy remains contested — HEAT-PPCI and MATRIX produced different conclusions than the older heparin-plus-GP-IIb/IIIa comparator trials, and the net clinical benefit of bivalirudin in the GP-IIb/IIIa-sparing era depends on factors (bleeding risk, access site, post-PCI infusion, antiplatelet strategy) that have not been jointly randomized.
- 03Pediatric dosing and long-term safety — bivalirudin is used off-label in pediatric CPB and ECMO, particularly for HIT, but dose-finding, monitoring thresholds, and long-term outcome data are limited.
- 04ECMO and VAD anticoagulation protocols are not standardized — individual-center protocols for initial infusion rate, monitoring target, and circuit interaction vary substantially, and optimal practice is still being defined.
- 05Role in HIT-related cardiac surgery beyond CPB — evidence for use in valve surgery, transplant, and complex reoperation in HIT-positive patients is primarily observational.
- 06Reversal strategies — no specific antidote exists, and while drug clearance is usually sufficient, studies of pharmacologic or extracorporeal reversal strategies for massive hemorrhage under bivalirudin are limited.
- 07Cost-effectiveness relative to generic heparin in different health-system contexts has moved since generic bivalirudin entered the US market in 2015, but updated comprehensive cost-effectiveness analyses are sparse.
Forms & Administration
Bivalirudin is supplied as a sterile lyophilized powder for intravenous use, reconstituted and diluted for bolus and infusion administration by trained cath-lab or critical-care personnel. The standard PCI regimen is a 0.75 mg/kg IV bolus followed by a 1.75 mg/kg/hr infusion for the duration of the procedure, with dose reduction required for moderate-to-severe renal impairment (1 mg/kg/hr for CrCl <30 mL/min; 0.25 mg/kg/hr for hemodialysis patients). Post-PCI infusion durations of up to 4 hours are typical in contemporary protocols, particularly in STEMI (see BRIGHT-4 2–4 hour high-dose infusion). Activated clotting time (ACT) monitoring is standard during PCI, with target ACT typically >300 seconds. For HIT or non-PCI settings (CPB, ECMO), dosing protocols are institution-specific and typically adjusted to aPTT or anti-IIa activity targets. This is a prescription-only hospital medication administered under direct physician supervision in a monitored setting; it is not suitable for outpatient or self-administered use under any circumstances.
Dosing & Protocols
The ranges below reflect protocols commonly discussed in the literature and by clinicians — not a prescription. Actual dosing for any individual should be determined by a qualified healthcare provider who knows the patient.
Typical Range
Standard PCI dose: 0.75 mg/kg IV bolus immediately before the procedure, followed by 1.75 mg/kg/hr continuous IV infusion for the duration of the procedure. In many contemporary STEMI protocols the 1.75 mg/kg/hr infusion is continued for up to 4 hours post-PCI (as in the BRIGHT-4 design) to mitigate early stent thrombosis risk. For patients with CrCl <30 mL/min, the maintenance infusion is reduced to 1 mg/kg/hr; for patients on hemodialysis, the infusion is reduced further to 0.25 mg/kg/hr. The bolus does not require renal adjustment. For CPB and ECMO (off-label), dosing is institution-specific — typical CPB protocols use a 1 mg/kg IV bolus plus 50 mg in the pump prime with a 2.5 mg/kg/hr infusion titrated to kaolin-ACT >400 seconds; typical ECMO protocols begin at 0.03-0.15 mg/kg/hr and titrate to target aPTT.
Frequency
Continuous IV infusion during the procedure, with no intermittent or scheduled outpatient dosing. This is a procedural anticoagulant, not a chronic medication.
Timing Considerations
No specific timing requirements: can be administered at any time of day, with or without food, and is not tied to exercise timing. Consistency matters more than the specific clock — dose at roughly the same time each day (or same day each week, for weekly protocols) to keep exposure steady.
Cycle Length
Duration is procedural — typically 1–4 hours for PCI (covering the case plus optional post-PCI infusion), hours-to-days for CPB (case length), and days-to-weeks for ECMO (circuit support duration). There is no wellness-style cycle.
Protocol Notes
Activated clotting time (ACT) monitoring is standard during PCI. Target ACT is typically >300 seconds; because bivalirudin has a more predictable dose-response than heparin, re-dosing for ACT drift is less frequent but monitoring remains mandatory. For CPB and ECMO, aPTT or anti-IIa activity monitoring is used depending on center protocol; ACT targets in CPB are typically >400-480 seconds. Switching from heparin to bivalirudin: most PCI protocols allow a direct switch — heparin is stopped and bivalirudin bolus is given 30 minutes later or when ACT falls. In HIT patients already anticoagulated with argatroban, a washout period may be required before initiating bivalirudin or before transitioning to warfarin to avoid double-anticoagulation confusion on INR monitoring (both agents affect INR, complicating warfarin bridging). Bleeding management: because bivalirudin has a short half-life (~25 minutes with normal renal function), holding the infusion is often sufficient for moderate bleeding. Severe bleeding may require transfusion support. Hemodialysis can partially remove the drug. There is no specific reversal agent. Hypersensitivity reactions, including rare anaphylaxis, have been reported. Re-exposure should be considered carefully in patients with a prior hypersensitivity history; premedication and close monitoring are reasonable precautions where re-exposure is essential.
Bivalirudin is FDA-approved only for intravenous anticoagulation during PCI and related procedural indications. Use for CPB, ECMO, and non-PCI HIT management is off-label and institution-protocol-driven. This is a hospital-administered intravenous medication that should only be given by trained cath-lab, cardiac surgery, or critical-care personnel with appropriate coagulation monitoring. There is no legitimate outpatient, wellness, or self-administered use.
Timeline of Effects
Onset
Immediate. Bivalirudin exerts anticoagulant effect within minutes of IV bolus administration — activated clotting time (ACT) typically rises above therapeutic threshold (300 seconds for PCI) within 5 minutes, which is why it can be dosed directly before the procedural access step without a pre-loading delay.
Peak Effect
Steady-state plasma concentration is achieved within 5–10 minutes of initiating the maintenance infusion. Peak anticoagulant effect coincides with steady-state and is maintained throughout the infusion at predictable levels given normal renal function.
After Discontinuation
Plasma half-life is approximately 25 minutes in patients with normal renal function; anticoagulant effect (ACT, aPTT) substantially normalizes within 1–2 hours of infusion discontinuation. In moderate renal impairment the half-life extends to approximately 34 minutes; in severe impairment to approximately 57 minutes; in dialysis patients to approximately 3.5 hours. The rapid clearance is a key practical advantage for hemostasis at vascular access sites and post-procedural hemorrhage management.
Common Questions
Who Bivalirudin Is NOT For
- •Active major bleeding — ongoing gastrointestinal, intracranial, retroperitoneal, or surgical hemorrhage is an absolute contraindication to initiating or continuing bivalirudin.
- •Known hypersensitivity to bivalirudin or any formulation component; rare anaphylactic reactions have been reported.
- •Severe uncontrolled hypertension — relative contraindication given procedural bleeding risk.
- •Recent intracranial hemorrhage, recent major surgery (including neurosurgery), or recent major trauma — relative contraindications requiring careful risk-benefit discussion.
- •Severe bleeding diathesis (e.g., severe hemophilia, severe thrombocytopenia) where the underlying condition cannot be corrected.
- •Pregnancy and lactation — limited human data; use only when clearly necessary and under specialist supervision. Bivalirudin has not been associated with teratogenicity in available data but the evidence base is small.
- •Severe renal impairment without appropriate dose reduction — full-dose infusion in CrCl <30 mL/min or dialysis without dose adjustment substantially increases bleeding risk.
Drug & Supplement Interactions
Bivalirudin is eliminated predominantly by intravascular proteolysis with a minor renal component, and does not undergo hepatic cytochrome P450 metabolism or meaningful hepatic glucuronidation. Consequently, pharmacokinetic drug-drug interactions mediated by CYP enzymes or hepatic transporters are not expected and no dose adjustment is required for concomitant CYP inhibitors or inducers. The dominant interactions are pharmacodynamic and involve additive bleeding risk with other anticoagulants, antiplatelets, and fibrinolytics. Concurrent administration with unfractionated heparin, low-molecular-weight heparins, fondaparinux, argatroban, warfarin, direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran), and fibrinolytics (alteplase, tenecteplase, reteplase) substantially increases bleeding risk and requires careful management — typically either overlap avoidance or tightly controlled bridging. For patients transitioning to warfarin from bivalirudin (e.g., HIT patients starting long-term oral anticoagulation), a washout or overlap strategy is standard, and clinicians must remember that direct thrombin inhibitors can falsely elevate INR, complicating warfarin dose titration during the overlap. Antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, GP IIb/IIIa inhibitors) are routinely used concurrently with bivalirudin during PCI — this is the intended combination in contemporary ACS protocols, not an interaction to avoid. However, the bleeding burden is additive, and dual or triple antiplatelet-plus-anticoagulant regimens require bleeding risk stratification. The specific combination of bivalirudin plus a planned GP IIb/IIIa inhibitor was the comparator strategy in REPLACE-2 and is now used only for selective bailout in most contemporary protocols. NSAIDs, SSRIs, and herbal anticoagulants (ginkgo, high-dose fish oil) can additively increase bleeding risk in the procedural period, though the clinical significance in a supervised inpatient setting is usually modest. As always, the operative reference for specific dose-adjustment and interaction guidance is the institutional protocol and the current FDA prescribing information, not this summary.
Safety Profile
Common Side Effects
Cautions
- • Acute stent thrombosis risk in the first 24 hours after PCI — signal in HEAT-PPCI and MATRIX, particularly when post-PCI infusion is discontinued abruptly; many protocols now use a prolonged post-PCI high-dose infusion to mitigate this
- • Dose reduction required for moderate-to-severe renal impairment and for dialysis patients — clearance is meaningfully renal-dependent
- • No specific reversal agent — emergency reversal relies on supportive care and drug clearance over time
- • Concurrent use with heparin, warfarin, or DOACs increases bleeding risk; switchover must be managed carefully by the proceduralist
- • Hypersensitivity reactions (rare) including anaphylaxis have been reported; previous tolerance does not guarantee future tolerance
What We Don't Know
Optimal post-PCI infusion duration and dose remain an area of active debate — the prolonged high-dose infusion used in BRIGHT-4 (2–4 hours post-procedure) is not yet universal. Best protocols for CPB, ECMO, and pediatric use are less standardized than for PCI, and dosing strategies vary meaningfully between centers. Long-term effects of repeated exposures (e.g., serial PCI patients) have not raised specific safety signals but have not been formally catalogued.
Legal Status
United States
FDA-approved (December 15, 2000) as Angiomax for use as an anticoagulant in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, with subsequent label expansion to cover PCI more broadly and to include patients with or at risk of heparin-induced thrombocytopenia/thrombosis. Generic bivalirudin entered the US market in 2015 following patent expiration and is now widely available. Prescription-only hospital medication administered by a licensed proceduralist or intensivist; not a controlled substance. There is no legitimate outpatient, retail, or self-administered channel — the drug is supplied only to hospitals, surgical centers, and specialty pharmacies serving those facilities.
International
Approved in the EU (EMA), UK, Canada, Australia, Japan, China, and most major markets with equivalent procedural-anticoagulation indications. Multiple generic manufacturers globally. In many jurisdictions it appears on national essential-medicines and hospital formularies as a core interventional-cardiology anticoagulant.
Sports & Competition
Bivalirudin is not specifically listed on the WADA Prohibited List. It has no plausible performance-enhancing mechanism and its hospital-only administration pattern makes accidental or intentional athletic use essentially absent. Athletes who require bivalirudin therapeutically (e.g., HIT requiring PCI or cardiac surgery) should document the indication in standard medical disclosures; competition participation following such cardiac events is a separate clinical question.
Regulatory status changes over time. Verify current local rules with a qualified professional.
Myths & Misconceptions
Myth
Bivalirudin is just a more expensive version of heparin.
Reality
The mechanisms are fundamentally different. Heparin is an indirect anticoagulant that requires antithrombin III to inactivate thrombin, cannot inactivate fibrin-bound thrombin, and can trigger heparin-induced thrombocytopenia (HIT) through antibody-mediated platelet activation. Bivalirudin is a direct thrombin inhibitor that binds thrombin itself at two sites, inactivates both free and clot-bound thrombin, does not require a cofactor, and cannot cause HIT because it has no structural similarity to heparin and does not form complexes with platelet factor 4. In HIT-positive patients, heparin is contraindicated and bivalirudin is a legitimate alternative — these are not interchangeable molecules.
Myth
Bivalirudin always reduces bleeding compared to heparin.
Reality
It depends on the comparator. Against heparin plus a planned glycoprotein IIb/IIIa inhibitor (REPLACE-2, HORIZONS-AMI, ISAR-REACT 4), bivalirudin consistently reduced major bleeding by roughly 40%. Against heparin monotherapy (HEAT-PPCI, MATRIX), the bleeding advantage narrows or disappears, and a small acute stent thrombosis signal can offset ischemic benefits. BRIGHT-4 (2022) reopened the question by using a prolonged post-PCI bivalirudin infusion and showed a renewed bleeding and mortality benefit. The honest answer is that the net benefit depends on the specific comparator regimen and the post-PCI infusion strategy — not on bivalirudin versus heparin in the abstract.
Myth
Bivalirudin is useful for outpatient or chronic anticoagulation.
Reality
It is not. Bivalirudin has a plasma half-life of approximately 25 minutes and is administered only as a continuous IV infusion during procedures or in the ICU. There is no oral form, no subcutaneous form, and no depot formulation. Chronic outpatient anticoagulation uses warfarin or a direct oral anticoagulant (apixaban, rivaroxaban, edoxaban, dabigatran). Anyone offering 'bivalirudin' for personal or home use is either confused, misusing the term, or operating outside legitimate medical practice.
Myth
Bivalirudin is identical to hirudin, the leech anticoagulant.
Reality
Bivalirudin was inspired by hirudin but is a distinct molecule. Hirudin is a 65-amino-acid natural peptide from leech saliva with irreversible, essentially non-dissociable binding to thrombin. Bivalirudin is a designed 20-amino-acid synthetic peptide that captures the bivalent binding logic of hirudin (active site + exosite 1) but has a self-limiting cleavage mechanism — thrombin slowly cuts the active-site-binding segment, releasing the enzyme after a few minutes. This is what gives bivalirudin its short, predictable pharmacodynamic profile, the key property that made it usable as a procedural anticoagulant. Recombinant hirudin derivatives (lepirudin, desirudin) were also developed clinically but have different pharmacokinetics and a different safety profile, and are less commonly used today.
Myth
Bivalirudin has a bleeding-reversal agent like some newer anticoagulants do.
Reality
No specific antidote exists. For the DOACs, specific reversal agents have been developed: idarucizumab for dabigatran, andexanet alfa for apixaban and rivaroxaban. For bivalirudin, clinicians rely on its short half-life — discontinuation plus supportive measures (mechanical compression, transfusion, fresh frozen plasma or prothrombin complex concentrate in severe cases) usually suffices because the drug clears within 1–2 hours in normal renal function. Hemodialysis can partially remove bivalirudin in patients with renal impairment. The absence of a specific antidote is usually not a clinical problem because of the pharmacokinetic profile, but it does argue for caution in patients with severe renal failure where half-life is prolonged.
Published Research
48 studiesBivalirudin in Extracorporeal Membrane Oxygenation
Bivalirudin anticoagulation for cardiopulmonary bypass during cardiac surgery
Bivalirudin Versus Heparin During PCI in NSTEMI: Individual Patient Data Meta-Analysis of Large Randomized Trials
Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial (BRIGHT-4)
Han et al., Lancet 2022. Randomized 6,000 STEMI patients undergoing primarily radial-access primary PCI in China to bivalirudin with a 2–4 hour post-PCI high-dose infusion vs. heparin monotherapy. The bivalirudin arm reduced the 30-day composite of all-cause mortality or BARC 3-5 major bleeding. The most recent large trial favoring bivalirudin when a prolonged post-PCI infusion is used, and a reference point for contemporary STEMI protocols.
Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation
Is bivalirudin an alternative anticoagulant for extracorporeal membrane oxygenation (ECMO) patients? A systematic review and meta-analysis
The Use of Bivalirudin in Pediatric Cardiac Surgery and in the Interventional Cardiology Suite
Efficacy and safety of bivalirudin vs heparin in patients with coronary heart disease undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials
Bivalirudin Anticoagulation Dosing Protocol for Extracorporeal Membrane Oxygenation: A Retrospective Review
Bivalirudin or unfractionated heparin in acute coronary syndromes (MATRIX)
Valgimigli et al., BMJ/NEJM 2015. Randomized 7,213 ACS patients to bivalirudin vs. heparin. Co-primary MACE endpoint was not significantly different, but bivalirudin reduced net adverse clinical events and all-cause mortality (29% relative reduction) with ~45-50% less major bleeding. One of the largest ACS anticoagulation trials ever conducted and a core modern data point in the heparin-vs-bivalirudin debate.
Critical Appraisal of Bivalirudin versus Heparin for Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials
Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting
Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials
Cavender and Sabatine, Lancet 2014. Meta-analysis of 16 trials and 33,958 patients comparing bivalirudin-based vs. heparin-based regimens. Bivalirudin increased myocardial infarction and stent thrombosis risk but decreased bleeding, with magnitude of bleeding reduction dependent on concomitant GP IIb/IIIa use. Widely cited benchmark for the bivalirudin risk-benefit tradeoff.
Bivalirudin versus heparin in patients treated with percutaneous coronary intervention: a meta-analysis of randomised trials
Unfractionated heparin versus bivalirudin in primary percutaneous coronary intervention (HEAT-PPCI): an open-label, single centre, randomised controlled trial
Shahzad et al., Lancet 2014. Single-center (Liverpool) all-comers STEMI trial randomizing 1,812 patients to heparin monotherapy vs. bivalirudin, with bailout-only GP IIb/IIIa use. Bivalirudin had more MACE (8.7% vs. 5.7%) driven by acute stent thrombosis, with no bleeding advantage. The trial that most clearly challenged bivalirudin's role when heparin monotherapy — rather than heparin + GP IIb/IIIa — was the comparator.
Bivalirudin for the treatment of patients with confirmed or suspected heparin-induced thrombocytopenia
Bivalirudin started during emergency transport for primary PCI (EUROMAX)
Steg et al., NEJM 2013. Randomized 2,218 STEMI patients receiving pre-hospital (ambulance-initiated) anticoagulation to bivalirudin vs. heparin ± GP IIb/IIIa. Bivalirudin reduced 30-day death or major bleeding (5.1% vs. 8.5%, p<0.001) but increased acute stent thrombosis. Established pre-hospital bivalirudin feasibility and re-raised the acute stent thrombosis signal.
Reduction in cardiac mortality with bivalirudin in patients with and without major bleeding: The HORIZONS-AMI trial
One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial
Bivalirudin dosing adjustments for reduced renal function with or without hemodialysis in the management of heparin-induced thrombocytopenia
Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
3-year follow-up of HORIZONS-AMI, Stone et al., Lancet 2011. Bivalirudin monotherapy preserved lower all-cause mortality (5.9% vs. 7.7%), cardiac mortality (2.9% vs. 5.1%), reinfarction (6.2% vs. 8.2%), and non-CABG major bleeding (6.9% vs. 10.5%) at 3 years vs. heparin + GP IIb/IIIa. Established durability of the early bleeding and mortality benefit.
Bivalirudin: a review of the pharmacology and clinical application
Safety and effectiveness of bivalirudin in routine care of patients undergoing percutaneous coronary intervention
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
The Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction (HORIZONS-AMI) Trial: study design and rationale
Bivalirudin during primary PCI in acute myocardial infarction (HORIZONS-AMI)
Landmark STEMI trial, Stone et al., NEJM 2008. Randomized 3,602 patients with STEMI undergoing primary PCI to bivalirudin alone or heparin + GP IIb/IIIa inhibitor. Bivalirudin reduced 30-day net adverse clinical events (9.2% vs. 12.1%) driven by lower major bleeding (4.9% vs. 8.3%) and lower cardiac mortality (1.8% vs. 2.9%) and all-cause mortality (2.1% vs. 3.1%), with an early but numerically small increase in acute stent thrombosis. The pivotal STEMI evidence for bivalirudin.
Bivalirudin in percutaneous coronary intervention
Bivalirudin: pharmacology and clinical applications
Evaluation of bivalirudin treatment for heparin-induced thrombocytopenia in critically ill patients with hepatic and/or renal dysfunction
Treatment of heparin-induced thrombocytopenia: is there a role for bivalirudin?
Use of bivalirudin as an anticoagulant during cardiopulmonary bypass
Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patients with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial)
Bivalirudin in PCI: an overview of the REPLACE-2 trial
Evolving role of bivalirudin in percutaneous coronary interventions; impact of the REPLACE-2 study
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial
Pivotal Phase 3 trial, Lincoff et al., JAMA 2003. Randomized 6,010 patients undergoing urgent or elective PCI to bivalirudin with provisional GP IIb/IIIa inhibition vs. heparin + planned GP IIb/IIIa inhibition. Bivalirudin was statistically non-inferior on the composite ischemic endpoint and significantly reduced in-hospital major bleeding (2.4% vs. 4.1%, p<0.001). REPLACE-2 established bivalirudin's core PCI use case and drove widespread US uptake.
Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose, and gender
Core pharmacokinetic study demonstrating that bivalirudin clearance is dependent on renal function: clearance falls approximately 45% in moderate renal impairment and 68% in severe impairment, with dialysis reducing clearance by ~70% and extending half-life from ~25 minutes to ~3.5 hours. The evidence base underlying the renal-adjusted dosing recommendations in the FDA label.
Bivalirudin: a new approach to anticoagulation
Bivalirudin: a direct thrombin inhibitor
Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study
The use of bivalirudin in patients with renal impairment
Bivalirudin: a new generation antithrombotic drug
A randomized comparison of bivalirudin and heparin in patients undergoing coronary angioplasty for postinfarction angina. Hirulog Angioplasty Study Investigators
Anticoagulant activity of Hirulog, a direct thrombin inhibitor, in humans
Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators
The original Bivalirudin Angioplasty Trial (BAT), Bittl et al., NEJM 1995. Randomized 4,312 patients undergoing angioplasty for unstable or postinfarction angina to bivalirudin or heparin. Overall primary endpoint was similar (11.4% vs. 12.2%) but bleeding was significantly lower with bivalirudin (3.8% vs. 9.8%, p<0.001), and the postinfarction-angina subgroup showed both ischemic and bleeding advantages. The foundational trial that established the drug's bleeding-reduction profile.
Structure-function relationships of hirulog peptide interactions with thrombin
Design and characterization of hirulogs: a novel class of bivalent peptide inhibitors of thrombin
The seminal 1990 Biochemistry paper by Maraganore and colleagues at Biogen defining the hirulog class. Describes the rational design of bivalent peptides that bridge the thrombin active site and exosite 1, with synthetic hirulog-1 shown to be approximately 2-fold more potent than native hirudin in prolonging activated partial thromboplastin time of human plasma. Hirulog-8 from this series became bivalirudin.
Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction (ISAR-REACT 4)
Kastrati et al., NEJM 2011. Randomized 1,721 NSTEMI patients to abciximab + heparin vs. bivalirudin. Primary composite outcome was similar (10.9% vs. 11.0%) but major bleeding was significantly lower with bivalirudin (2.6% vs. 4.7%, p=0.02). Extended the bivalirudin bleeding-advantage story from STEMI (HORIZONS-AMI) to the NSTEMI population.
Safety and Effectiveness of Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis
Quick Facts
- Class
- Direct Thrombin Inhibitor
- Evidence
- Strong
- Safety
- Well-Studied
- Updated
- Apr 2026
- Citations
- 48PubMed
Also known as
Tags
Related Goals
Evidence Score
Clinical Trials
View Clinical TrialsLinks to ClinicalTrials.gov for reference. Listing does not imply endorsement.